FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst

Immix Biopharma, Inc. (NASDAQ:IMMX) – Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for Immix Biopharma in a research report issued on Tuesday, December 9th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.77) per share for the year, up from their prior forecast of ($0.80). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.87) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2025 earnings at ($0.16) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.65) EPS.

IMMX has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Wednesday, October 8th. Zacks Research lowered shares of Immix Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 25th. Finally, Wall Street Zen downgraded shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 30th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.

Immix Biopharma Stock Up 2.0%

Shares of Immix Biopharma stock opened at $6.73 on Thursday. Immix Biopharma has a 12 month low of $1.34 and a 12 month high of $7.30. The stock has a market cap of $225.99 million, a PE ratio of -8.74 and a beta of 0.33. The business has a fifty day simple moving average of $3.66 and a 200-day simple moving average of $2.81.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05).

Institutional Investors Weigh In On Immix Biopharma

Several institutional investors have recently made changes to their positions in the company. Tritonpoint Wealth LLC acquired a new position in Immix Biopharma in the second quarter worth approximately $51,000. Velan Capital Investment Management LP acquired a new position in shares of Immix Biopharma during the 2nd quarter worth $52,000. Vanguard Group Inc. raised its holdings in shares of Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after purchasing an additional 31,625 shares in the last quarter. Tocqueville Asset Management L.P. lifted its stake in shares of Immix Biopharma by 37.4% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after purchasing an additional 10,950 shares during the last quarter. Finally, Imprint Wealth LLC bought a new stake in Immix Biopharma in the third quarter worth $141,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.